The invention claimed compounds as interleukin 17 (IL-17) inhibitors and tumor necrosis factor alpha (TNFα) inhibitors and further related to their use in the treatment of inflammatory or autoimmune diseases and other related pathologies. This evidence concerns the gene TNF and autoimmune disease.